NAAG peptidase inhibitors and their potential for diagnosis and therapy

Jia Zhou, Joseph H. Neale, Martin G. Pomper, Alan P. Kozikowski

Research output: Contribution to journalArticle

159 Citations (Scopus)

Abstract

Modulation of N-acetyl-L-aspartyl-L-glutamate peptidase activity with small-molecule inhibitors holds promise for a wide variety of diseases that involve glutamatergic transmission, and has implications for the diagnosis and therapy of cancer. This new class of compounds, of which at least one has entered clinical trials and proven to be well tolerated, has demonstrated efficacy in experimental models of pain, schizophrenia, amyotrophic lateral sclerosis, traumatic brain injury and, when appropriately functionalized, can image prostate cancer. Further investigation of these promising drug candidates will be needed to bring them to the marketplace. The recent publication of the X-ray crystal structure for the enzymatic target of these compounds should facilitate the development of other new agents with enhanced activity that could improve both the diagnosis and treatment of neurological disorders.

Original languageEnglish (US)
Pages (from-to)1015-1026
Number of pages12
JournalNature Reviews Drug Discovery
Volume4
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Glutamate Carboxypeptidase II
Protease Inhibitors
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Glutamic Acid
Prostatic Neoplasms
Schizophrenia
Peptide Hydrolases
Theoretical Models
X-Rays
Clinical Trials
Pain
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

NAAG peptidase inhibitors and their potential for diagnosis and therapy. / Zhou, Jia; Neale, Joseph H.; Pomper, Martin G.; Kozikowski, Alan P.

In: Nature Reviews Drug Discovery, Vol. 4, No. 12, 12.2005, p. 1015-1026.

Research output: Contribution to journalArticle

Zhou, Jia ; Neale, Joseph H. ; Pomper, Martin G. ; Kozikowski, Alan P. / NAAG peptidase inhibitors and their potential for diagnosis and therapy. In: Nature Reviews Drug Discovery. 2005 ; Vol. 4, No. 12. pp. 1015-1026.
@article{e7e3b984c6ae4dc99762e3ef608cd0ab,
title = "NAAG peptidase inhibitors and their potential for diagnosis and therapy",
abstract = "Modulation of N-acetyl-L-aspartyl-L-glutamate peptidase activity with small-molecule inhibitors holds promise for a wide variety of diseases that involve glutamatergic transmission, and has implications for the diagnosis and therapy of cancer. This new class of compounds, of which at least one has entered clinical trials and proven to be well tolerated, has demonstrated efficacy in experimental models of pain, schizophrenia, amyotrophic lateral sclerosis, traumatic brain injury and, when appropriately functionalized, can image prostate cancer. Further investigation of these promising drug candidates will be needed to bring them to the marketplace. The recent publication of the X-ray crystal structure for the enzymatic target of these compounds should facilitate the development of other new agents with enhanced activity that could improve both the diagnosis and treatment of neurological disorders.",
author = "Jia Zhou and Neale, {Joseph H.} and Pomper, {Martin G.} and Kozikowski, {Alan P.}",
year = "2005",
month = "12",
doi = "10.1038/nrd1903",
language = "English (US)",
volume = "4",
pages = "1015--1026",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - NAAG peptidase inhibitors and their potential for diagnosis and therapy

AU - Zhou, Jia

AU - Neale, Joseph H.

AU - Pomper, Martin G.

AU - Kozikowski, Alan P.

PY - 2005/12

Y1 - 2005/12

N2 - Modulation of N-acetyl-L-aspartyl-L-glutamate peptidase activity with small-molecule inhibitors holds promise for a wide variety of diseases that involve glutamatergic transmission, and has implications for the diagnosis and therapy of cancer. This new class of compounds, of which at least one has entered clinical trials and proven to be well tolerated, has demonstrated efficacy in experimental models of pain, schizophrenia, amyotrophic lateral sclerosis, traumatic brain injury and, when appropriately functionalized, can image prostate cancer. Further investigation of these promising drug candidates will be needed to bring them to the marketplace. The recent publication of the X-ray crystal structure for the enzymatic target of these compounds should facilitate the development of other new agents with enhanced activity that could improve both the diagnosis and treatment of neurological disorders.

AB - Modulation of N-acetyl-L-aspartyl-L-glutamate peptidase activity with small-molecule inhibitors holds promise for a wide variety of diseases that involve glutamatergic transmission, and has implications for the diagnosis and therapy of cancer. This new class of compounds, of which at least one has entered clinical trials and proven to be well tolerated, has demonstrated efficacy in experimental models of pain, schizophrenia, amyotrophic lateral sclerosis, traumatic brain injury and, when appropriately functionalized, can image prostate cancer. Further investigation of these promising drug candidates will be needed to bring them to the marketplace. The recent publication of the X-ray crystal structure for the enzymatic target of these compounds should facilitate the development of other new agents with enhanced activity that could improve both the diagnosis and treatment of neurological disorders.

UR - http://www.scopus.com/inward/record.url?scp=33644700192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644700192&partnerID=8YFLogxK

U2 - 10.1038/nrd1903

DO - 10.1038/nrd1903

M3 - Article

VL - 4

SP - 1015

EP - 1026

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 12

ER -